RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Key Takeaways RCKT's resubmitted BLA for Kresladi to treat severe LAD-I has been accepted by the FDA.FDA's decision is expected by March 28, 2026, with potential approval marking RCKT's first product.The resubmission follows an earlier FDA CRL for Kresladi BLA issued to RCKT last June.Rocket Pharmaceuticals (RCKT) announced that the FDA has accepted the resubmitted biologics license application (BLA) seeking approval for its gene therapy Kresladi (marnetegragene autotemcel; marne-cel) to treat patients with ...